Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Racura Oncology Ltd

RAC.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$1.41

▼ -0.75%

Market Cap $275.92M · Vol 52.66K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$275.92M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

43.12

Momentum

Beta

0.64

vs Market

52W High

$3.47

55.73% below

52W Low

$0.80

91.36% above

Volume

52.66K

Avg 82.55K

P/B

12.75

Price-to-book

ROE

N/A

Return on equity

Free Float

69.76%

Public shares

Shariah Compliance8 STANDARDS

✗ Racura Oncology Ltd (RAC.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RAC.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-7.64%

-21.46%

-7.21%

YTD

-26.92%

+71.24%

+141.86%

-36.06%

Financials & Valuation

TTM · Annual

Total Revenue	$518.78K
Net Income	$-3,150,011.00
Revenue Growth (YoY)	+731.79%
Gross Margin	100.00%
Operating Margin	-1,264.51%
Net Profit Margin	-607.20%
ROE	N/A
ROA · ROIC	-25.38% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	256.95
P/B	12.75
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	196.07M

Technical Indicators

50-Day SMA	$1.55
200-Day SMA	$1.81
RSI (14)	43.12
Beta	0.64
52-Week High	$3.47
52-Week Low	$0.80

Volume Today	52.66K
Avg Daily Volume (30D)	82.55K
Relative Volume	0.64x
Volatility (10D)	39.26
Volatility (30D)	40.13
Free Float	69.76%

Analyst Consensus

N/A

Current Price $1.41

Mean Target N/A

52W Low$0.80 52W High$3.47

Current

Target

$0.80 $3.47

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00CWVFMT3

ISINAU000000RAC3

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Racura Oncology Ltd, formerly Race Oncology Limited, is an Australia-based Phase III clinical biopharmaceutical company with a focus on cancer care. The Company's lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterized safety profile. The Company is advancing a formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase III clinical programs in acute myeloid leukemia (AML), a Phase I a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase I a/b program in combination with the anthracycline doxorubicin, where the Company is focused on delivering both cardioprotection and enhanced anticancer activity for solid tumor patients.